Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium

Por Li, M, Hurren, R, Zastawny, R L, Ling, V, Buick, R N
Publicado em 1999

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing

Por Wang, Z, Dove, P, Wang, X, Shamas-Din, A, Li, Z, Nachman, A, Oh, Y J, Hurren, R, Ruschak, A, Climie, S, Press, B, Griffin, C, Undzys, E, Aman, A, Al-awar, R, Kay, L E, O'Neill, D, Trudel, S, Slassi, M, Schimmer, A D
Publicado no Cell Death Dis (2015)